Patients treated with a fourth-generation fluoroquinolone for MRSA keratitis experienced similar visual acuity outcomes as those treated with vancomycin, according to a presenter at the virtual Association for Research in Vision and Ophthalmology meeting.
“Given the concern for antibiotic resistance, as well as corneal toxicity from fortified vancomycin, fluoroquinolone therapy for MRSA keratitis may be a reasonable initial treatment option with close monitoring,” Sarah Atta, BS, said.
Atta and colleagues evaluated 52 culture-proven cases of MRSA keratitis from 2008 to 2019 at the
Uncategorized